GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » Future 3-5Y Total Revenue Growth Rate

RVNC (Revance Therapeutics) Future 3-5Y Total Revenue Growth Rate : 23.57 (As of Dec. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate is 23.57.


Competitive Comparison of Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate falls into.



Revance Therapeutics  (NAS:RVNC) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Revance Therapeutics Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Executives
Dwight Moxie officer: SVP, GC & Secretary 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Dustin S Sjuts officer: President 7555 GATEWAY BLVD, NEWARK CA 94560
Tobin Schilke officer: Chief Financial Officer 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Carey Oconnor Kolaja director C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Vlad Coric director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin director C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud director C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne director, officer: CEO and President 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche officer: Principal Financial Officer 7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail officer: CFO, Seretary & EVP Corp Dev. 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell officer: SVP, GC & Secretary 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080